title: Nitric oxide synthase/COX cross-talk: nitric oxide activates COX-1 but inhibits COX-2-derived prostaglandin production.
abstract: It is recognized that there is molecular cross-talk between the inflammatory mediators NO and PGs that may regulate tissue homeostasis and contribute to pathophysiological processes. However, the literature is divided with respect to whether NO activates or inhibits PG production. In this study, we sought to determine whether conflicting observations could be accounted for by divergent effects of NO on the two cyclooxygenase (COX) isoforms. Exposure of resting macrophages to NO (30 microM) enhanced PGE2 release by 4. 5-fold. This enhancement was inhibited by indomethacin but not by the COX-2 selective inhibitor NS398. To separate the activation of phospholipase A2 and COX, we performed experiments using fibroblasts derived from COX-1-deficient or COX-2-deficient mice. These cells exhibit increased basal PG production, which is due to a constitutively stimulated cytosolic phospholipase A2 and enhanced basal expression of the remaining COX isozyme. The exposure of COX- 2-deficient cells to exogenous NO (10 microM) resulted in a 2.4-fold increase of PGE2 release above controls. Further studies indicated that NO stimulated PGE2 release in COX-2-deficient cells, without altering COX-1 mRNA or protein expression. In contrast, NO inhibited COX-2-derived PGE2 production in both LPS-stimulated macrophages and COX-1 knockout cells. This inhibition was associated with both decreased expression and nitration of COX-2. Thus, these studies demonstrate divergent effects of NO on the COX isoforms. The regulation of PGE production by NO is therefore complex and will depend on the local environment in which these pleiotropic mediators are produced.
authors.affiliation: Department of Rheumatology, Hospital for Joint Diseases and Division of Rheumatology, New York University School of Medicine, New York, NY 10003, USA.
authors.forename: R
authors.initials: R
authors.lastname: Clancy
authors.forename: B
authors.initials: B
authors.lastname: Varenika
authors.forename: W
authors.initials: W
authors.lastname: Huang
authors.forename: L
authors.initials: L
authors.lastname: Ballou
authors.forename: M
authors.initials: M
authors.lastname: Attur
authors.forename: A R
authors.initials: AR
authors.lastname: Amin
authors.forename: S B
authors.initials: SB
authors.lastname: Abramson
mesh_terms: D000818:Animals; D002450:Cell Communication / Q000276:immunology*; D002460:Cell Line; D002461:Cell Line, Transformed; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D015232:Dinoprostone / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D005347:Fibroblasts / Q000201:enzymology / Q000378:metabolism; D007399:Interphase / Q000276:immunology; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008262:Macrophage Activation / Q000276:immunology; D008264:Macrophages / Q000201:enzymology / Q000378:metabolism; D008565:Membrane Proteins; D051379:Mice; D009566:Nitrates / Q000378:metabolism; D009569:Nitric Oxide / Q000502:physiology; D019001:Nitric Oxide Synthase / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II; D011448:Prostaglandin Antagonists / Q000378:metabolism*; D011451:Prostaglandin-Endoperoxide Synthases / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D011453:Prostaglandins / Q000096:biosynthesis*; D015854:Up-Regulation / Q000276:immunology
chemical_list: D007527:Isoenzymes; D008070:Lipopolysaccharides; D008565:Membrane Proteins; D009566:Nitrates; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; C496512:Ptgs1 protein, mouse; D015232:Dinoprostone